Year None202120202019201820172016 Date Latest Press Release April 11, 2019 Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 March 26, 2019 Eiger BioPharmaceuticals to Participate in Conferences in April March 25, 2019 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 March 20, 2019 Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 March 14, 2019 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update March 13, 2019 Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 March 11, 2019 Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit February 27, 2019 Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer February 6, 2019 Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan February 4, 2019 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
